EA202190603A1 - Полипептиды анти-her2 и способы их применения - Google Patents

Полипептиды анти-her2 и способы их применения

Info

Publication number
EA202190603A1
EA202190603A1 EA202190603A EA202190603A EA202190603A1 EA 202190603 A1 EA202190603 A1 EA 202190603A1 EA 202190603 A EA202190603 A EA 202190603A EA 202190603 A EA202190603 A EA 202190603A EA 202190603 A1 EA202190603 A1 EA 202190603A1
Authority
EA
Eurasian Patent Office
Prior art keywords
her2
antibody
methods
bbb
application
Prior art date
Application number
EA202190603A
Other languages
English (en)
Russian (ru)
Inventor
Марк С. Деннис
Ванда Кван
Джозеф В. Льюкок
Джонатан Соколоски
Джой Ю Дзукеро
Original Assignee
Денали Терапьютикс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Денали Терапьютикс Инк. filed Critical Денали Терапьютикс Инк.
Publication of EA202190603A1 publication Critical patent/EA202190603A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EA202190603A 2018-08-22 2019-08-22 Полипептиды анти-her2 и способы их применения EA202190603A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862721505P 2018-08-22 2018-08-22
PCT/US2019/047728 WO2020041604A1 (en) 2018-08-22 2019-08-22 Anti-her2 polypeptides and methods of use thereof

Publications (1)

Publication Number Publication Date
EA202190603A1 true EA202190603A1 (ru) 2021-07-14

Family

ID=67989062

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190603A EA202190603A1 (ru) 2018-08-22 2019-08-22 Полипептиды анти-her2 и способы их применения

Country Status (15)

Country Link
US (1) US20220002436A1 (cg-RX-API-DMAC7.html)
EP (1) EP3840781A1 (cg-RX-API-DMAC7.html)
JP (3) JP2021534220A (cg-RX-API-DMAC7.html)
KR (1) KR20210074279A (cg-RX-API-DMAC7.html)
CN (1) CN113286610A (cg-RX-API-DMAC7.html)
AR (1) AR115998A1 (cg-RX-API-DMAC7.html)
AU (2) AU2019326545A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021002953A2 (cg-RX-API-DMAC7.html)
CA (1) CA3141815A1 (cg-RX-API-DMAC7.html)
EA (1) EA202190603A1 (cg-RX-API-DMAC7.html)
IL (2) IL326298A (cg-RX-API-DMAC7.html)
MX (1) MX2021001976A (cg-RX-API-DMAC7.html)
SG (1) SG11202101436SA (cg-RX-API-DMAC7.html)
TW (1) TW202017947A (cg-RX-API-DMAC7.html)
WO (1) WO2020041604A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS63818B1 (sr) 2017-02-17 2023-01-31 Denali Therapeutics Inc Konstruisani polipeptidi za vezivanje za receptor transferina
BR112020005271A2 (pt) 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
JP7543290B2 (ja) 2019-02-20 2024-09-02 デナリ セラピューティクス インコーポレイテッド 抗trem2抗体及びその使用方法
BR112022012230A2 (pt) 2019-12-23 2022-08-30 Denali Therapeutics Inc Variantes de progranulina
US11124567B2 (en) 2020-01-13 2021-09-21 Denali Therapeutics Inc. Anti-TREM2 antibodies and methods of use thereof
CA3170338A1 (en) * 2020-02-19 2021-08-26 Denali Therapeutics Inc. Engineered anti-her2 bispecific proteins
CR20230178A (es) 2020-10-14 2023-07-26 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas
IL311003A (en) 2021-08-25 2024-04-01 Denali Therapeutics Inc Anti-2HER antibodies and methods of using them
US20240392035A1 (en) * 2021-08-25 2024-11-28 Denali Therapeutics Inc. Engineered anti-her2 bispecific proteins
US20250066449A1 (en) * 2021-12-31 2025-02-27 Imnewrun, Inc. Blood-brain barrier permeable fusion protein and uses thereof
KR20240067001A (ko) * 2022-10-28 2024-05-16 주식회사 아임뉴런 뇌혈관장벽 투과성 융합 단백질 및 이의 용도
JP2025540336A (ja) * 2022-12-08 2025-12-11 アデル,インク 抗タウ抗体及びペプチドを含む融合体とその用途
CN120648654A (zh) * 2024-03-13 2025-09-16 深圳太力生物技术有限责任公司 重组细胞的制备方法、重组细胞及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE423140T1 (de) * 2005-01-05 2009-03-15 F Star Biotech Forsch & Entw Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
MX367126B (es) * 2012-08-29 2019-08-06 Hoffmann La Roche Transporte para atravesar la barrera hematoencefálica.
WO2014089209A2 (en) * 2012-12-04 2014-06-12 Abbvie, Inc. Blood-brain barrier (bbb) penetrating dual specific binding proteins
WO2015191934A2 (en) * 2014-06-11 2015-12-17 Abbvie Inc. Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases
JP7021955B2 (ja) * 2015-06-24 2022-03-03 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Her2及び血液脳関門受容体に特異的な三重特異性抗体及び使用方法
CN107446045A (zh) * 2016-07-22 2017-12-08 北京天广实生物技术股份有限公司 一种抗her2的抗体、其药物组合物及用途
RS63818B1 (sr) * 2017-02-17 2023-01-31 Denali Therapeutics Inc Konstruisani polipeptidi za vezivanje za receptor transferina
CA3053379A1 (en) * 2017-02-17 2018-08-23 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
WO2019032955A1 (en) * 2017-08-10 2019-02-14 Denali Therapeutics Inc. MODIFIED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES

Also Published As

Publication number Publication date
IL326298A (en) 2026-04-01
JP2021534220A (ja) 2021-12-09
KR20210074279A (ko) 2021-06-21
US20220002436A1 (en) 2022-01-06
IL280922B1 (en) 2026-03-01
CA3141815A1 (en) 2020-02-27
JP2026086616A (ja) 2026-05-26
CN113286610A (zh) 2021-08-20
JP7818042B2 (ja) 2026-02-19
IL280922B2 (en) 2026-07-01
AU2019326545A1 (en) 2021-03-11
AR115998A1 (es) 2021-03-25
IL280922A (en) 2021-04-29
TW202017947A (zh) 2020-05-16
EP3840781A1 (en) 2021-06-30
WO2020041604A1 (en) 2020-02-27
JP2024150674A (ja) 2024-10-23
BR112021002953A2 (pt) 2021-05-11
MX2021001976A (es) 2021-06-08
AU2026200081A1 (en) 2026-01-29
SG11202101436SA (en) 2021-03-30

Similar Documents

Publication Publication Date Title
MX2022000652A (es) Anticuerpos contra claudina 18 y metodos de tratamiento del cancer.
PH12021550802A1 (en) Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
AR115998A1 (es) Polipéptidos anti-her2 y métodos de uso de los mismos
SA520420748B1 (ar) أجسام مضادة للمركب الترابطي شبيه دلتا 3 /مجموعة من التمايز 3 ثنائية الخاصية
MX2025012685A (es) Anticuerpos para claudin6 y metodos para tratar el cancer
PH12022550195A1 (en) Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses
MX2023007520A (es) Aglutinantes de albumina de suero mejorados.
EA201791666A1 (ru) Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123
MX2025010630A (es) Aglutinantes de albumina serica mejorados
MX2023005374A (es) Aglutinantes de albumina serica mejorados.
PH12021500051A1 (en) Cd3 antigen binding fragments and compositions comprising same
MX2024006968A (es) Anticuerpos cdh17 y metodos de tratamiento del cancer.
MX2023001256A (es) Proteínas que comprenden dominios de unión al antígeno hla-g y sus usos.
MX2024003355A (es) Anticuerpos anti-cd3.
EA201990321A1 (ru) Биспецифические антителоподобные связывающие белки, которые специфически связываются с cd3 и cd123
EA201992755A1 (ru) Новые моноклональные антитела к белку 4, ассоциированному с цитотоксическими т-лимфоцитами, (ctla-4)
MX2021011330A (es) Anticuerpos de claudina-6 y conjugados de fármacos.
ATE509032T1 (de) Chimerizierte gm-csf antikörper
EA201992467A1 (ru) ГЕТЕРОДИМЕРИЗУЮЩИЕСЯ ДОМЕНЫ Ig
MX2023011712A (es) Anticuerpos anti receptor de adhesion acoplado a proteinas g e2 (adgre2) y usos de los mismos.
MX2021010877A (es) Moleculas de union a cumulo de diferenciacion 3 (cd3).
EA202092593A1 (ru) Белки, связывающие каннабиноидный рецептор 1-го типа (cb1), и их применение
EA201790341A1 (ru) Анти-ск8 антитела для применения в лечении рака
BR112022010824A2 (pt) Anticorpo bifuncional contra pd-l1 e tgf¿
JOP20230223A1 (ar) بولي ببتيد ربط gucy2c واستخداماته